Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Personalized Treatment Aided by Automated Analysis of Fluid in Active Neovascular Age-related Macular Degeneration (nAMD) in a Prospective, Multicenter, Randomized Study.
Authors not listed
Medical University of Vienna · 2021
Abstract
The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-09 MST
Cite this
APA
Anonymous. (2021). Personalized Treatment Aided by Automated Analysis of Fluid in Active Neovascular Age-related Macular Degeneration (nAMD) in a Prospective, Multicenter, Randomized Study. <em>Medical University of Vienna</em>. https://clinicaltrials.gov/study/NCT05093374
Vancouver
Anonymous. Personalized Treatment Aided by Automated Analysis of Fluid in Active Neovascular Age-related Macular Degeneration (nAMD) in a Prospective, Multicenter, Randomized Study. Medical University of Vienna. 2021.
BibTeX
@misc{anon2021Person,
title = {Personalized Treatment Aided by Automated Analysis of Fluid in Active Neovascular Age-related Macular Degeneration (nAMD) in a Prospective, Multicenter, Randomized Study.},
author = {Anonymous},
journal = {Medical University of Vienna},
year = {2021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Ophthalmology 2012
Preprint · OA
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Ophthalmology 2006
Citation only
Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
Skyline Therapeutics 2025
Open access · US-GOV
A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)
St. Erik Eye Hospital 2017
Open access · US-GOV
Recurrent Neovascular Age-related Macular Degeneration After Discontinuation of VEGF Inhibitors Managed in a Treat and Extend Regimen
Novartis Pharmaceuticals 2014
Open access · US-GOV
A 3 Months, patient-and Rater Blinded, Randomized, Prospective Study Comparing Systemic Anti-VEGF Effects Between Ranibizumab and Aflibercept in Treatment naïve Neovascular Age-related Macular Degeneration (nAMD) Patients
Klinikum Bremen-Mitte, gGmbH 2008
Open access · US-GOV